Concord Biotech Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹312 Cr +26.3% YoYSee revenue, profit and what management said. You are viewing Q4 FY26.
CB

Concord Biotech Ltd

Q4 FY26Pharmaceuticals & Biotechnology

Concord Biotech Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹326Cr
−24.2% YoY
+17.3% QoQ
Net profit
₹90Cr
−36.6% YoY
+32.4% QoQ
Margin
38%
−6 pp YoY
+1 pp QoQ
Price₹1,571
Market cap₹14.5K Cr
P/E51.0

The short version

Concord Biotech expects strong revenue growth in FY27, likely exceeding their historical growth rate of around 18%. - There is good visibility for growth starting from Q1 and Q2 of FY27. - The company anticipates volume growth in APIs, particularly in anti-infective and oncology segments, driven by new product launches (e.g., Nystatin, Fusidic Acid). - Capacity utilization is progressively improving with Unit 1 at optimal capacity and Unit 3 around 50%, supporting growth without immediate large capex. - The manufacturing capacities across units can support peak revenue potential of approximately INR 3,000 crores. - Growth levers include new injectables facility, U.S. Concord Biotech expects strong growth in FY27, with visibility for growth starting from Q1 and Q2. - Historical growth rate around 18%; FY27 growth is expected to be slightly better than this. - Operating leverage from injectables and Stellon Biotech U.S.

From Concord Biotech Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Concord Biotech expects strong revenue growth in FY27, likely exceeding their historical growth rate of around 18%.
  • There is good visibility for growth starting from Q1 and Q2 of FY27.
  • The company anticipates volume growth in APIs, particularly in anti-infective and oncology segments, driven by new product launches (e.g., Nystatin, Fusidic Acid).
  • Capacity utilization is progressively improving with Unit 1 at optimal capacity and Unit 3 around 50%, supporting growth without immediate large capex.
  • The manufacturing capacities across units can support peak revenue potential of approximately INR 3,000 crores.
  • Growth levers include new injectables facility, U.S. subsidiary Stellon Biotech, CDMO opportunities, and topical range facility.

2 more points from Concord Biotech Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Concord Biotech Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Current year capex guidance is around INR 20-30 crores, mainly for maintenance and smaller growth projects.
  • No large capex expected this year unless new projects require it, e.g., additional facility for topical range planned this financial year.
  • Recently commissioned facilities include soft gel facility and injectable plant; some capex spent on modifications for a large-volume innovator project.
  • Next substantial capex tranche (above INR 50-100 crores) likely 2-3 years out, with any very large additions 4-5 years away.

2 more points from Concord Biotech Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Concord Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • Concord Biotech has significant visibility on the orderbook for the first half of FY27.
  • Inventory levels are slightly elevated but mostly linked to identified customer demand or forecasts, especially outside the Middle East.
  • In the Middle East, inventory is primarily API-related due to staggered approaches caused by geopolitical challenges; formulation inventory is not held due to shelf life issues.
  • Some tenders, especially in the Middle East formulations, were delayed in FY26 but remain work in progress.
  • The timing issues in tender execution affected FY26 but are expected to normalize with gradual supplies in FY27.

2 more points from Concord Biotech Ltd's call on order book

Create a free account to keep reading this call

Concord Biotech Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Concord Biotech Ltd Q4 FY26 results — key figures

Concord Biotech Ltd Q4 FY26 reported results vs Q4 FY25, ₹ crore
₹ CrQ4 FY26Q4 FY25YoYQ3 FY26QoQ
Revenue326430-24.2%278+17.3%
Operating profit (EBITDA)122190-35.8%102+19.6%
Operating margin38%44%-6 pp37%+1 pp
Profit before tax118185-36.2%90+31.1%
Net profit (PAT)90142-36.6%68+32.4%
EPS (₹)4.306.78-36.6%3.24+32.7%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹312 Cr, net profit ₹76 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Balaxi Pharma (Q4 FY26)

    Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY

  • Accretion Pharmaceuticals (Q4 FY26)

    45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks

  • Gujarat Themis Biosyn (Q4 FY26)

    . Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.

  • Aptus Pharma (Q4 FY26)

    The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Concord Biotech Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Concord Biotech Ltd Q4 FY26 results?

Concord Biotech expects strong revenue growth in FY27, likely exceeding their historical growth rate of around 18%. - There is good visibility for growth starting from Q1 and Q2 of FY27. - The company anticipates volume growth in APIs, particularly in anti-infective and oncology segments, driven by new product launches (e.g., Nystatin, Fusidic Acid). - Capacity utilization is progressively improving with Unit 1 at optimal capacity and Unit 3 around 50%, supporting growth without immediate large capex. - The manufacturing capacities across units can support peak revenue potential of approximately INR 3,000 crores. - Growth levers include new injectables facility, U.S. Concord Biotech expects strong growth in FY27, with visibility for growth starting from Q1 and Q2. - Historical growth rate around 18%; FY27 growth is expected to be slightly better than this. - Operating leverage from injectables and Stellon Biotech U.S.

What is Concord Biotech Ltd share price analysis?

Concord Biotech Ltd currently shows a neutral. The stock trades at a P/E of 51.0 with a market cap of ₹14,489 Cr. Investors should review the full earnings analysis for detailed insights.

Is Concord Biotech Ltd planning capital expenditure?

Current year capex guidance is around INR 20-30 crores, mainly for maintenance and smaller growth projects. - No large capex expected this year unless new projects require it, e.g., additional facility for topical range planned this financial year. - Recently commissioned facilities include soft gel facility and injectable plant; some capex spent on modifications for a large-volume innovator project. - Next substantial capex tranche (above INR 50-100 crores) likely 2-3 years out, with any very large additions 4-5 years away. - Existing capacities are adequate to support turnover up to INR 3,000 crores; future capex mostly for debottlenecking/maintenance or new customer-driven projects. - Strategic growth levers include expansion in injectables, CDMO through Stellon Biotech (U.S.

Keep Concord Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.